Back to results
US 2003/0215463 A1Published application
Means of inducing durable immune responses
OwnerDavid Knipe, Mark Brockmaninventors
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerDavid Knipe, Mark Brockmaninventors
Estimating the term…
A replication defective herpes virus vector is described. The replication defective herpes virus vector has a deletion of at least a fragment of a UL29 gene that is replaced with a heterologous sequence encoding an antigen from a specific infectious disease agent. The vector can express said antigen. Prior HSV infection did not diminish the magnitude or the durability of the IgG antibody response generated by preferred replication-defective HSV-1 vectors. A method of inducing in a mammal an immune response against a specific infectious disease agent also is described. A recombinant replication defective mutant Herpes Simplex Virus as a vaccine is administered to a mammal to elicit in the mammal an immune response against the infectious disease causing agent.
A method of inducing in a mammal an immune response against a specific infectious disease agent, the method comprising:
A vector comprising a replication defective herpes virus vector, wherein the replication defective herpes virus vector comprises a deletion of at least a fragment of a UL29 gene and replacing said deletion with a heterologous sequence encoding an antigen from a specific infectious disease agent, wherein said vector can express said antigen.
A replication defective recombinant mutant herpes simplex virus vector capable of infecting mammalian cells, the vector comprising at least about one heterologous gene inserted into a region where at least a fragment of a UL29 gene was deleted, the deletion being non essential for viral replication, wherein, either:
Dependencies are inferred from the claim text.